2,246 press releases in English indexed under biotech & pharma.
Presentations to cover updates across Eikon’s clinical pipeline including:
Four rapid oral presentations at ESMO will feature new data for INCB161734, a KRAS G12D inhibitor, and INCA33890 1 , a TGFβR2×PD-1 bispecific antibody Both investigational therapies are being evaluated in ongoing Phase 3 programs Incyte will host an investor event and webcast on Monday, October 26, 2026 from 7:30 – 9:00 C
Conference call will take place on Monday, October 19, 2026, at 8:00 am ET NEW HAVEN, Conn., October 18, 2026--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it wi
WATERTOWN, Mass., Oct. 18, 2026 -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will host a corporate webcast to discuss topline results from the APOLLO Phase 3 trial of bitopertin in EPP. The webcast will be held on Monday, October 19, 2026 at 8:00 a.m. ET.
Financing supports Antheia's domestic manufacturing strategy to onshore critical medicine supply chains MENLO PARK, Calif., Oct. 18, 2026 -- Antheia, the advanced biosynthesis company delivering 21st-century pharmaceutical manufacturing and innovation, today announced it has...
New York, New York--(October 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...
NEW YORK, Oct. 18, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline.
WALTHAM, Mass., Oct. 18, 2026 -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced presentations at United European Gastroenterology Week (UEGW) 2026 in Barcelona. The presentations include the first scientific congress presentation of clinical data across all three of Spyre’s IBD antibodies—SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23)—which are now being tested as monotherapies and pairwise combinations in the SKYLINE study, as well as new preclinical data demonstrating additive efficacy of these complementary mechanisms.
SEOUL, South Korea and SHANGHAI, Oct. 18, 2026 -- New clinical data for XellSmart's off-the-shelf cell therapy for Parkinson's Disease was presented at the International Congress of Parkinson's Disease and Movement Disorders (MDS), one of the world's most prestigious...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. -...
GENEVA, Switzerland and HYDERABAD, India -- Cotecna, a leading provider of Testing, Inspection and Certification (TIC) services, today announced the acquisition of Energon Labs, a cGMP-compliant, USFDA-inspected, ISO 9001:2015 and ISO 17025:2017 certified analytical testing laboratory based in Hyderabad, India.
Industry-Leading Pulse Oximetry Platform Now Features First-of-Its-Kind Atrial Fibrillation (AFib) Detection with Previously Cleared AI-Enabled Opioid-Induced Respiratory Depression (OIRD) Detection Designed Together to Deliver Earlier Clinical Insights IRVINE, Calif., Oct. 17, 2026...